We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tourette

News List

Teva’s Austedo flunks in late-stage paediatric Tourette study pharmatimes
March 10, 2020
Teva has announced that Austedo (deutetrabenazine) failed to meet its primary endpoints of reduction in motor and phonic tics in moderate-to-severe paediatric Tourette syndrome.
New Treatment Guideline Focuses on Tourette Syndrome drugs
May 09, 2019
New Treatment Guideline Focuses on Tourette Syndrome.
Neurocrine slumps as Tourette’s drug fails clinical trial pharmaphorum
December 14, 2018
Shares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed the mark.
Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program biospace
April 10, 2018
TEL AVIV, Israel, April 9, 2018 Therapix Ltd. (NASDAQ: TRPX) ("Therapix" or "the Company"), announced today topline results from its investigator-initiated Phase IIa study at Yale University
Is extended-release guanfacine effective in children with chronic tic disorders? europeanpharmaceuticalreview
July 28, 2017
A new study has assessed the safety, tolerability, and effectiveness of extended-release guanfacine in children 6-17 years of age who have chronic tic disorders including Tourette’s disorder.